MCID: LCL006
MIFTS: 60

Localized Scleroderma

Categories: Rare diseases, Skin diseases, Immune diseases, Neuronal diseases, Nephrological diseases, Respiratory diseases, Bone diseases, Genetic diseases

Aliases & Classifications for Localized Scleroderma

MalaCards integrated aliases for Localized Scleroderma:

Name: Localized Scleroderma 12 50 56 14 69
Morphea 12 50 52 69
Localized Fibrosing Scleroderma 50 56
Scleroderma, Circumscribed or Localized 12
Unspecified Circumscribed Scleroderma 12
Localized Scleroderma [ambiguous] 12
Circumscribed Scleroderma Nos 12
Circumscribed Scleroderma 12
Scleroderma, Localized 50
Localised Morphoea 12
Localized Morphea 12

Characteristics:

Orphanet epidemiological data:

56
localized scleroderma
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: normal life expectancy;

Classifications:

Orphanet: 56  
Rare skin diseases


External Ids:

Disease Ontology 12 DOID:8472
ICD10 33 L94.0
ICD9CM 35 701.0
MeSH 42 D012594
NCIt 47 C72069
Orphanet 56 ORPHA90289
MESH via Orphanet 43 D012594
UMLS via Orphanet 70 C0036420
ICD10 via Orphanet 34 L94.0
UMLS 69 C0036420

Summaries for Localized Scleroderma

NIH Rare Diseases : 50 localized scleroderma is characterized by thickening of the skin from excessive collagen deposits. collagen is a protein normally present in our skin that provides structural support. however, when too much collagen is made, the skin becomes stiff and hard. localized types of scleroderma are those limited to the skin and related tissues and, in some cases, the muscle below. internal organs are not affected by localized scleroderma, and localized scleroderma can never progress to the systemic form of the disease. often, localized conditions improve or go away on their own over time, but the skin changes and damage that occur when the disease is active can be permanent. for some people, localized scleroderma is serious and disabling. there are two generally recognized types of localized scleroderma: morphea and linear.   last updated: 4/3/2012

MalaCards based summary : Localized Scleroderma, also known as morphea, is related to calcinosis and rheumatoid arthritis, and has symptoms including hyperpigmentation of the skin, hypopigmentation of the skin and cigarette-paper scars. An important gene associated with Localized Scleroderma is MMP1 (Matrix Metallopeptidase 1), and among its related pathways/superpathways are GPCR Pathway and TGF-Beta Pathway. The drugs Vaccines and Bosentan have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and bone, and related phenotypes are growth/size/body region and cellular

Wikipedia : 72 Morphea, also called localized scleroderma or circumscribed scleroderma, is a form of scleroderma that... more...

Related Diseases for Localized Scleroderma

Diseases in the Systemic Scleroderma family:

Scleroderma, Familial Progressive Localized Scleroderma

Diseases related to Localized Scleroderma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 172)
id Related Disease Score Top Affiliating Genes
1 calcinosis 29.0 CTGF IL6 TGFB1 TNF
2 rheumatoid arthritis 28.3 IL6 MMP1 MMP13 TGFB1 TNF
3 systemic scleroderma 11.6
4 linear scleroderma 11.3
5 atrophoderma of pierini and pasini 11.0
6 hypereosinophilic syndrome 10.6 BMP6 TGFB1
7 autosomal recessive congenital ichthyosis 10.6 MMP1 TGFB1
8 strawberry gallbladder 10.6 BMP6 TGFB1
9 urticaria 10.5 SMAD3 TGFB1
10 acromicric dysplasia 10.5 CTGF TGFB1
11 pulmonary hypertension 10.5 MMP1 TNF
12 biemond syndrome 10.5 TGFB1 TNF
13 smarca4-deficient sarcoma of thorax 10.4 IL6 TNF
14 pneumoconiosis due to talc 10.4 BMP6 TNF
15 aortic arch interruption 10.4 IL6 TNF
16 osteogenesis imperfecta, type x 10.4 IL6 MMP1
17 cutaneous leishmaniasis 10.4 IL6 TNF
18 plantar wart 10.4 TGFB1 TNF
19 spirillary rat-bite fever 10.4 IL6 TNF
20 ohdo syndrome, maat-kievit-brunner type 10.4 BMP6 DCN TGFB1
21 toxoplasmosis 10.4 IL6 TNF
22 asphyxia neonatorum 10.4 IL6 SELE
23 dyslexia 5 10.4 IL6 TNF
24 beare-stevenson cutis gyrata syndrome 10.4 BMP6 DCN TGFB1
25 epstein-barr virus hepatitis 10.4 IL6 TNF
26 anencephaly and spina bifida x-linked 10.4 IL6 TNF
27 antigen-peptide-transporter 2 deficiency 10.4 IL6 TNF
28 keratopathy 10.4 MMP1 SMAD3 TGFB1
29 infancy electroclinical syndrome 10.4 IL6 SELE
30 papilledema 10.4 IL6 TNF
31 not otherwise specified 3-mga-uria type 10.4 BMP6 TNF
32 congenital methemoglobinemia 10.3 BMP6 SMAD3 TGFB1
33 upper gum cancer 10.3 IL6 TNF
34 bipolar i disorder 10.3 IL6 TNF
35 twin-to-twin transfusion syndrome 10.3 DCN SMAD3 TGFB1
36 salt and pepper syndrome 10.3 CTGF MMP1 TGFB1
37 anhidrosis 10.3 BMP6 CTGF TGFB1
38 lymphocytic colitis 10.3 IL6 TNF
39 pasteurellosis 10.3 IL6 TNF
40 tinea favosa 10.3 IL6 TNF
41 central nervous system leiomyosarcoma 10.2 IL6 TNF
42 oligomeganephronic renal hypoplasia 10.2 DCN MMP1
43 urethral intrinsic sphincter deficiency 10.2 SELE TNF
44 indolent myeloma 10.2 IL6 TNF
45 stargardt macular degeneration absent or hypoplastic corpus callosum mental retardation and dysmorphic features 10.2 IL6 TNF
46 pulmonary valve insufficiency 10.2 CTGF SMAD3 TGFB1
47 hypotrichosis-lymphedema-telangiectasia-renal defect syndrome 10.2 SELE TNF
48 acquired thrombocytopenia 10.2 IL6 MMP1 TNF
49 residual stage corticosteroid-induced glaucoma 10.2 IL6 MMP1 TNF
50 chronic inflammatory demyelinating polyradiculoneuropathy 10.2 CTGF SMAD3 TGFB1

Comorbidity relations with Localized Scleroderma via Phenotypic Disease Network (PDN):


Systemic Scleroderma Vulva Cancer

Graphical network of the top 20 diseases related to Localized Scleroderma:



Diseases related to Localized Scleroderma

Symptoms & Phenotypes for Localized Scleroderma

Human phenotypes related to Localized Scleroderma:

56 32 (show all 16)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hyperpigmentation of the skin 56 32 hallmark (90%) Very frequent (99-80%) HP:0000953
2 hypopigmentation of the skin 56 32 hallmark (90%) Very frequent (99-80%) HP:0001010
3 cigarette-paper scars 56 32 hallmark (90%) Very frequent (99-80%) HP:0001073
4 split hand 56 32 occasional (7.5%) Occasional (29-5%) HP:0001171
5 arthralgia 56 32 occasional (7.5%) Occasional (29-5%) HP:0002829
6 skeletal muscle atrophy 56 32 frequent (33%) Frequent (79-30%) HP:0003202
7 scarring alopecia of scalp 56 32 occasional (7.5%) Occasional (29-5%) HP:0004552
8 flexion contracture of toe 56 32 occasional (7.5%) Occasional (29-5%) HP:0005830
9 stiff skin 56 32 hallmark (90%) Very frequent (99-80%) HP:0030053
10 hemiatrophy of lower limb 56 32 occasional (7.5%) Occasional (29-5%) HP:0100557
11 hemiatrophy of upper limb 56 32 occasional (7.5%) Occasional (29-5%) HP:0100558
12 lipoatrophy 56 32 occasional (7.5%) Occasional (29-5%) HP:0100578
13 myalgia 56 32 occasional (7.5%) Occasional (29-5%) HP:0003326
14 dermal atrophy 56 Very frequent (99-80%)
15 hemiatrophy 56 Occasional (29-5%)
16 flexion contracture 56 Occasional (29-5%)

UMLS symptoms related to Localized Scleroderma:


exanthema, pruritus

MGI Mouse Phenotypes related to Localized Scleroderma:

44 (show all 11)
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.09 BMP6 CTGF DCN IL6 MMP13 SELE
2 cellular MP:0005384 10.08 CTGF DCN IL6 MMP13 SELE SMAD3
3 homeostasis/metabolism MP:0005376 10.06 CTGF DCN IL6 MMP1 MMP13 SELE
4 cardiovascular system MP:0005385 10.04 CTGF IL6 MMP13 SELE SMAD3 TGFB1
5 integument MP:0010771 9.97 CTGF DCN IL6 MMP13 SELE SMAD3
6 digestive/alimentary MP:0005381 9.93 CTGF DCN IL6 SMAD3 TGFB1 TNF
7 neoplasm MP:0002006 9.73 DCN IL6 MMP1 SMAD3 TGFB1 TNF
8 liver/biliary system MP:0005370 9.72 IL6 SELE SMAD3 TGFB1 TNF
9 respiratory system MP:0005388 9.63 DCN IL6 SELE TGFB1 TNF CTGF
10 skeleton MP:0005390 9.56 TNF BMP6 CTGF DCN IL6 MMP13
11 vision/eye MP:0005391 9.17 CTGF DCN IL6 SELE SMAD3 TGFB1

Drugs & Therapeutics for Localized Scleroderma

Drugs for Localized Scleroderma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 143)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4
2
Bosentan Approved, Investigational Phase 2, Phase 3 147536-97-8 104865
3
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
4
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
5
Lenograstim Approved Phase 3 135968-09-1
6
Lidocaine Approved, Vet_approved Phase 2, Phase 3 137-58-6 3676
7
Tadalafil Approved, Investigational Phase 3 171596-29-5 110635
8
Acetylcholine Approved Phase 3 51-84-3 187
9
Alginic acid Approved, Experimental Phase 3 9005-32-7
10
Domperidone Approved, Investigational, Vet_approved Phase 3 57808-66-9 3151
11
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
12
Omeprazole Approved, Investigational, Vet_approved Phase 3 73590-58-6 4594
13
Glucosamine Approved, Nutraceutical Phase 2, Phase 3 3416-24-8 439213
14 Phosphodiesterase 5 Inhibitors Phase 3
15 Phosphodiesterase Inhibitors Phase 3
16 Sildenafil Citrate Phase 3 171599-83-0
17 Vasodilator Agents Phase 3,Phase 2
18 Antirheumatic Agents Phase 3,Phase 2,Phase 1
19 Antihypertensive Agents Phase 2, Phase 3,Phase 1
20 Endothelin Receptor Antagonists Phase 2, Phase 3
21 Calcium, Dietary Phase 3,Phase 2,Phase 1
22 Adjuvants, Immunologic Phase 3
23 Interferon Inducers Phase 3
24 interferons Phase 3,Phase 1
25 Alkylating Agents Phase 3,Phase 2,Phase 1
26 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
27 Anesthetics Phase 2, Phase 3
28 Anesthetics, Local Phase 2, Phase 3
29 Anti-Arrhythmia Agents Phase 2, Phase 3
30 Anticoagulants Phase 2, Phase 3, Phase 1
31 Antimetabolites Phase 2, Phase 3,Phase 1
32 Central Nervous System Depressants Phase 2, Phase 3
33 Diuretics, Potassium Sparing Phase 2, Phase 3
34 Fibrinolytic Agents Phase 2, Phase 3
35 Glucuronyl glucosamine glycan sulfate Phase 2, Phase 3
36 Hypoglycemic Agents Phase 2, Phase 3
37 Hypolipidemic Agents Phase 2, Phase 3
38 Lipid Regulating Agents Phase 2, Phase 3
39 Peripheral Nervous System Agents Phase 2, Phase 3, Phase 1
40 Pharmaceutical Solutions Phase 2, Phase 3
41 Sodium Channel Blockers Phase 2, Phase 3
42 abobotulinumtoxinA Phase 3
43 Botulinum Toxins Phase 3
44 Botulinum Toxins, Type A Phase 3
45 Cholinergic Agents Phase 3
46 insulin Phase 3
47 Insulin, Globin Zinc Phase 3
48 Neuromuscular Agents Phase 3
49 Neurotransmitter Agents Phase 3
50 onabotulinumtoxinA Phase 3

Interventional clinical trials:

(show top 50) (show all 81)

id Name Status NCT ID Phase Drugs
1 Influenza Vaccination in Patients With Scleroderma Unknown status NCT01002508 Phase 4
2 Imiquimod in Children With Plaque Morphea Completed NCT00147771 Phase 3 Imiquimod 5% cream
3 Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY Completed NCT01295736 Phase 3 Sildenafil;placebo
4 High Dose Cyclophosphamide for Treatment of Scleroderma Completed NCT00501995 Phase 3 IV Cyclophosphamide
5 Effectiveness and Safety of Lidocaine for Scleroderma Completed NCT00740285 Phase 2, Phase 3 Lidocaine 2% without vessel constrictor
6 A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Completed NCT01117298 Phase 3 Tadalafil;Placebo
7 Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome Completed NCT02165111 Phase 3 Onabotulinumtoxin A;sterile saline solution
8 Gastroesophageal Reflux Treatment in Scleroderma Completed NCT01878526 Phase 3 Alginic acid;placebo (for domperidone);Domperidone;placebo (of alginic acid)
9 Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma Completed NCT00070590 Phase 2, Phase 3 Bosentan
10 Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis Completed NCT01347008 Phase 3 Sildenafil citrate;Placebo (Sugar pill)
11 Scleroderma Lung Disease Completed NCT00004563 Phase 3 Cyclophosphamide;Placebo
12 Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study Withdrawn NCT00230373 Phase 3 imiquimod 5% cream (Aldara)
13 A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy Unknown status NCT00936546 Phase 2 Rituximab
14 Zibotentan Better Renal Scleroderma Outcome Study Unknown status NCT02047708 Phase 2 Zibotentan
15 Efficacy and Safety of Imatinib in Scleroderma Completed NCT00479934 Phase 2 imatinib mesylate
16 Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix Completed NCT00129428 Phase 1, Phase 2
17 Effect of Bosentan in Scleroderma Renal Crisis Completed NCT01241383 Phase 2 Bosentan
18 Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine Completed NCT00775463 Phase 2 treprostinil diethanolamine;placebo
19 Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis Completed NCT00764309 Phase 1, Phase 2 dasatinib
20 Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma Completed NCT00278525 Phase 2 standard of care
21 Oral Type I Collagen for Relieving Scleroderma Completed NCT00005675 Phase 2 Oral bovine type I collagen;Placebo
22 A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma) Completed NCT00442611 Phase 1, Phase 2 Abatacept;Abatacept
23 Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital Ulcers Completed NCT02801305 Phase 2 Diltiazem Gel 2%;Nitroglycerin Ointment 2%;Vaseline
24 Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II) Completed NCT00883129 Phase 2 Mycophenolate mofetil;Cyclophosphamide;Placebo
25 Psychological Treatments for Scleroderma Completed NCT00007267 Phase 2
26 Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease Completed NCT01559129 Phase 2 Pomalidomide (CC-4047);Placebo
27 Pirfenidone Plus M-DDO Gel in Moderate and Severe Acne Recruiting NCT03076320 Phase 1, Phase 2
28 Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma Recruiting NCT02370784 Phase 2 atorvastatin;Placebo
29 Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells Recruiting NCT02213705 Phase 1, Phase 2
30 Riociguat in Scleroderma Associated Digital Ulcers Recruiting NCT02915835 Phase 2 Riociguat;Placebo
31 Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension Recruiting NCT02682511 Phase 2 Oral Ifetroban;Oral Placebo
32 IL1-TRAP, Rilonacept, in Systemic Sclerosis Active, not recruiting NCT01538719 Phase 1, Phase 2 Rilonacept
33 Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate Not yet recruiting NCT03221257 Phase 2 Pirfenidone (PFD);Placebo (Plac);Mycophenolate Mofetil (MMF)
34 Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma Terminated NCT01545427 Phase 2 Imatinib mesylate
35 Placebo Controlled Trial of Bosentan in Scleroderma Patients Terminated NCT00377455 Phase 2 Bosentan;Placebo
36 A Study of the Safety and Tolerability of MEDI-551 in Scleroderma Completed NCT00946699 Phase 1
37 A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma Completed NCT00930683 Phase 1 MEDI-546;MEDI-546;MEDI-546;MEDI-546;MEDI-546;MEDI-546;MEDI-546;MEDI-546;MEDI-546
38 Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma Recruiting NCT02426229 Phase 1 dabigatran etexilate
39 Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients Terminated NCT00040651 Phase 1 Fludarabine;Cyclophosphamide;Thymoglobulin
40 Comparative Effectiveness Trial in the Treatment of Pediatric Plaque Morphea Withdrawn NCT02680717 Phase 1 Clobetasol;Calcipotriene;Tacrolimus
41 Fractional Carbon Dioxide Laser Versus UVA 1 in Treatment of Localized Scleroderma Unknown status NCT02002897
42 Treatment Study Comparing UVA-1 Phototherapy Versus Placebo Treatment for Morphea Unknown status NCT01799174
43 Empirical Comparative Study of Variation Blood Level Antibody Vitamin D at Scleroderma (SSc) Patients Compared Healthy Peoples Unknown status NCT01553890
44 Prevention and Treatment of Digital Ulcers in Systemic Sclerosis Unknown status NCT01836263
45 Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea. Completed NCT00812188
46 The CARRA Registry Completed NCT01697254
47 UVA1 Light for Treatment of Scleroderma and Similar Conditions Completed NCT00476801
48 Morbidity and Mortality Follow Up for the Scleroderma Lung Study Completed NCT01762449
49 Finger Hardness Measure in Scleroderma Completed NCT01111786
50 Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement Completed NCT00333437 Mycophenolate mofetil

Search NIH Clinical Center for Localized Scleroderma

Genetic Tests for Localized Scleroderma

Anatomical Context for Localized Scleroderma

MalaCards organs/tissues related to Localized Scleroderma:

39
Skin, Lung, Bone, Endothelial, Bone Marrow, Breast, Skeletal Muscle

Publications for Localized Scleroderma

Articles related to Localized Scleroderma:

(show top 50) (show all 372)
id Title Authors Year
1
Periostin in Mature Stage Localized Scleroderma. ( 28566901 )
2017
2
Anti-dense Fine Speckled 70 Autoantibodies in Japanese Children with Dermatomyositis, Localized Scleroderma, and Idiopathic Arthritis with Iridocyclitis. ( 28461535 )
2017
3
Localized scleroderma: clinical and epidemiological features with emphasis on adulthood- versus childhood-onset disease differences. ( 28271552 )
2017
4
Musculoskeletal MRI findings of juvenile localized scleroderma. ( 28091699 )
2017
5
The role of local temperature and other clinical characteristics of localized scleroderma as markers of disease activity. ( 27943304 )
2017
6
Quantitative Assessment of Skin Stiffness in Localized Scleroderma Using Ultrasound Shear-Wave Elastography. ( 28457631 )
2017
7
European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. ( 28792092 )
2017
8
Thrombocytopenia Associated with Localized Scleroderma: Report of Four Pediatric Cases and Review of the Literature. ( 28543515 )
2017
9
Neurological abnormalities in localized scleroderma of the face and head: a case series study for evaluation of imaging findings and clinical course. ( 27700194 )
2016
10
Fractional carbon dioxide laser versus low-dose UVA-1 phototherapy for treatment of localized scleroderma:A a clinical and immunohistochemical randomized controlled study. ( 27510285 )
2016
11
Oxidative stress parameters in localized scleroderma patients. ( 27591994 )
2016
12
Lupus erythematosus and localized scleroderma coexistent at the same sites: a rare presentation of overlap syndrome of connective-tissue diseases. ( 27274545 )
2016
13
Is Localized Scleroderma Caused by Borrelia burgdorferi? ( 27387068 )
2016
14
BILATERAL CHOROIDAL EXCAVATION IN JUVENILE LOCALIZED SCLERODERMA. ( 27533641 )
2016
15
Correlation of clinical tools to determine activity of localized scleroderma in paediatric patients. ( 26138783 )
2016
16
Use of Mycophenolate Mofetil in Patients with Severe Localized Scleroderma Resistant or Intolerant to Methotrexate. ( 26582717 )
2016
17
Predictors of Longitudinal Quality of Life in Pediatric Localized Scleroderma. ( 27696700 )
2016
18
Esophageal abnormalities in juvenile localized scleroderma: is it associated with other extracutaneous manifestations? ( 27693175 )
2016
19
Localized scleroderma en coup de sabre in the Neurology Clinic. ( 27456882 )
2016
20
Evaluation of serum concentrations of the selected cytokines in patients with localized scleroderma. ( 26985179 )
2016
21
Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy. ( 26577237 )
2016
22
Measurement of transepidermal water loss in localized scleroderma. ( 26970329 )
2016
23
Drug Survival and Predictors of Drug Survival for Methotrexate Treatment in a Retrospective Cohort of Adult Patients with Localized Scleroderma. ( 26983450 )
2016
24
Mild Cognitive Impairment as a single sign of brain hemiatrophy in patient with Localized Scleroderma and Parry-Romberg Syndrome. ( 27154452 )
2016
25
German guidelines for the diagnosis and therapy of localized scleroderma. ( 26819124 )
2016
26
Localized Scleroderma: A Clinical Review. ( 27604889 )
2016
27
Lichen sclerosus associated with localized scleroderma: dermoscopy contribution. ( 27579757 )
2016
28
A systematic review of tools for determining activity of localized scleroderma in paediatric and adult patients. ( 27401109 )
2016
29
Localized Scleroderma of Lower Extremities:Clinical and Magnetic Resonance Imaging Features. ( 26564453 )
2015
30
Successful autologous hematopoietic stem cell transplantation for a patient with rapidly progressive localized scleroderma. ( 25923607 )
2015
31
A Case Report of Successful Treatment of Recalcitrant Childhood Localized Scleroderma with Infliximab and Leflunomide. ( 26161155 )
2015
32
Systemic involvement in localized scleroderma/morphea. ( 26321403 )
2015
33
Localized Scleroderma Presenting as Port-wine Stains: Report of Two Cases and a Literature Review. ( 25791763 )
2015
34
Clinical and laboratory features of systemic sclerosis complicated with localized scleroderma. ( 25582037 )
2015
35
Assessment of esophageal involvement in systemic sclerosis and morphea (localized scleroderma) by clinical, endoscopic, manometric and pH metric features: a prospective comparative hospital based study. ( 25888470 )
2015
36
Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles. ( 26254121 )
2015
37
The efficacy of dantrolene sodium for muscle cramps in patients with localized scleroderma. ( 26559172 )
2015
38
Durometry as an Outcome Measure in Juvenile Localized Scleroderma. ( 26302039 )
2015
39
Juvenile localized scleroderma with port wine stain: coincidental or possible common pathogenetic association. ( 25814757 )
2015
40
Localized scleroderma: clinical spectrum and therapeutic update. ( 25672301 )
2015
41
Recurrence rates in localized scleroderma (morphoea). ( 25776242 )
2015
42
Disease recurrence in localized scleroderma: a retrospective analysis of 344 patients with pediatric or adult-onset disease. ( 25381928 )
2014
43
Perineural inflammation in morphea (localized scleroderma): systematic characterization of a poorly recognized but potentially useful histopathological feature. ( 24117981 )
2014
44
Localized scleroderma variants: pharmacologic implications. ( 22905721 )
2014
45
United Kingdom survey of current management of juvenile localized scleroderma. ( 24850875 )
2014
46
Pirfenidone gel in patients with localized scleroderma: a phase II study. ( 25533576 )
2014
47
Lipomatosis of the mons pubis secondary to localized scleroderma (Morphea): first report of surgical management. ( 25370577 )
2014
48
Antiphospholipid antibodies in localized scleroderma: the potential role of screening tests for the detection of antiphospholipid syndrome. ( 25097470 )
2014
49
A rare case of acquired partial lipodystrophy (Barraquer-Simons syndrome) with localized scleroderma. ( 23675994 )
2014
50
Co-existence of Lichen Sclerosus and Localized Scleroderma in Female Monozygotic Twins. ( 24841519 )
2014

Variations for Localized Scleroderma

Expression for Localized Scleroderma

Search GEO for disease gene expression data for Localized Scleroderma.

Pathways for Localized Scleroderma

Pathways related to Localized Scleroderma according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.6 BMP6 CTGF IL6 MMP1 MMP13 SMAD3
2
Show member pathways
13.43 BMP6 CTGF IL6 SMAD3 TGFB1 TNF
3
Show member pathways
13.17 BMP6 CTGF IL6 SMAD3 TGFB1 TNF
4
Show member pathways
12.78 IL6 SMAD3 TGFB1 TNF
5
Show member pathways
12.66 DCN MMP1 MMP13 TGFB1
6 12.58 IL6 MMP1 SMAD3 TGFB1
7
Show member pathways
12.57 BMP6 CTGF IL6 TGFB1 TNF
8
Show member pathways
12.5 IL6 SMAD3 TGFB1 TNF
9 12.33 IL6 SMAD3 TGFB1 TNF
10
Show member pathways
12.22 IL6 MMP1 MMP13 TNF
11 12.15 BMP6 SMAD3 TGFB1
12
Show member pathways
12.15 MMP1 SELE TGFB1
13 12.14 IL6 TGFB1 TNF
14
Show member pathways
12.04 IL6 SMAD3 TGFB1
15 12.04 BMP6 CTGF SMAD3 TGFB1
16
Show member pathways
12.01 IL6 SMAD3 TGFB1
17 11.99 MMP1 SMAD3 TGFB1
18 11.97 BMP6 SMAD3 TGFB1
19 11.94 IL6 MMP1 SMAD3 TGFB1 TNF
20 11.93 IL6 TGFB1 TNF
21 11.92 IL6 SMAD3 TGFB1 TNF
22 11.88 IL6 SELE TNF
23 11.87 IL6 SMAD3 TGFB1
24
Show member pathways
11.86 IL6 TGFB1 TNF
25 11.84 IL6 MMP1 TGFB1 TNF
26
Show member pathways
11.83 MMP1 MMP13 TNF
27
Show member pathways
11.82 IL6 SMAD3 TGFB1
28 11.81 IL6 TGFB1 TNF
29
Show member pathways
11.79 IL6 SMAD3 TGFB1
30 11.74 BMP6 DCN IL6 TGFB1
31 11.72 IL6 MMP1 SELE
32 11.69 IL6 MMP1 TGFB1 TNF
33 11.68 IL6 TGFB1 TNF
34 11.63 BMP6 CTGF IL6 TGFB1
35 11.63 IL6 TGFB1 TNF
36 11.59 BMP6 MMP13 TGFB1
37 11.54 SMAD3 TGFB1 TNF
38 11.5 CTGF IL6 TGFB1 TNF
39 11.47 CTGF SMAD3 TGFB1
40
Show member pathways
11.47 IL6 MMP1 SELE TNF
41 11.43 CTGF IL6 TNF
42 11.4 IL6 SMAD3 TNF
43 11.35 IL6 SELE SMAD3 TGFB1 TNF
44 11.27 IL6 MMP1 SMAD3 TGFB1
45 11.26 IL6 SELE TNF
46 11.23 DCN IL6 MMP1
47 11.16 IL6 TGFB1 TNF
48 11.15 IL6 SELE TGFB1 TNF
49 11.13 BMP6 IL6 TNF
50 11.11 CTGF SMAD3

GO Terms for Localized Scleroderma

Cellular components related to Localized Scleroderma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 BMP6 CTGF DCN DEFB1 IL6 MMP1
2 extracellular matrix GO:0031012 9.56 DCN MMP1 MMP13 TGFB1
3 proteinaceous extracellular matrix GO:0005578 9.55 CTGF DCN MMP1 MMP13 TGFB1
4 Golgi lumen GO:0005796 9.5 DCN DEFB1 TGFB1
5 extracellular space GO:0005615 9.28 BMP6 CTGF DCN DEFB1 IL6 MMP13

Biological processes related to Localized Scleroderma according to GeneCards Suite gene sharing:

(show all 47)
id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.95 BMP6 DEFB1 IL6 SMAD3 TNF
2 leukocyte migration GO:0050900 9.87 MMP1 SELE TGFB1 TNF
3 positive regulation of protein phosphorylation GO:0001934 9.86 CTGF TGFB1 TNF
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.85 IL6 TGFB1 TNF
5 response to organic cyclic compound GO:0014070 9.85 CTGF IL6 TGFB1
6 defense response to Gram-positive bacterium GO:0050830 9.82 DEFB1 IL6 TNF
7 positive regulation of protein kinase B signaling GO:0051897 9.82 IL6 TGFB1 TNF
8 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.81 IL6 TGFB1 TNF
9 extracellular matrix disassembly GO:0022617 9.8 DCN MMP1 MMP13
10 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.8 CTGF IL6 TGFB1 TNF
11 inflammatory response GO:0006954 9.8 BMP6 IL6 SELE TGFB1 TNF
12 response to wounding GO:0009611 9.79 CTGF IL6 TGFB1
13 response to glucocorticoid GO:0051384 9.79 BMP6 IL6 TNF
14 aging GO:0007568 9.78 CTGF DCN IL6 TGFB1
15 positive regulation of epithelial cell proliferation GO:0050679 9.77 BMP6 IL6 TGFB1
16 SMAD protein signal transduction GO:0060395 9.76 BMP6 SMAD3 TGFB1
17 T cell activation GO:0042110 9.73 IL6 SMAD3 TGFB1
18 positive regulation of gene expression GO:0010628 9.72 CTGF IL6 SMAD3 TGFB1 TNF
19 protein import into nucleus, translocation GO:0000060 9.7 TGFB1 TNF
20 endochondral ossification GO:0001958 9.7 BMP6 MMP13
21 positive regulation of collagen biosynthetic process GO:0032967 9.7 CTGF TGFB1
22 positive regulation of protein complex assembly GO:0031334 9.69 TGFB1 TNF
23 negative regulation of myoblast differentiation GO:0045662 9.69 TGFB1 TNF
24 cell-cell junction organization GO:0045216 9.68 SMAD3 TGFB1
25 positive regulation of pri-miRNA transcription from RNA polymerase II promoter GO:1902895 9.68 SMAD3 TGFB1
26 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.68 SMAD3 TGFB1
27 positive regulation of chondrocyte differentiation GO:0032332 9.67 BMP6 SMAD3
28 positive regulation of chemokine production GO:0032722 9.67 IL6 TNF
29 leukocyte tethering or rolling GO:0050901 9.66 SELE TNF
30 acute inflammatory response GO:0002526 9.66 DEFB1 IL6
31 lens fiber cell differentiation GO:0070306 9.65 SMAD3 TGFB1
32 positive regulation of SMAD protein import into nucleus GO:0060391 9.65 BMP6 TGFB1
33 negative regulation of lipid storage GO:0010888 9.64 IL6 TNF
34 SMAD protein complex assembly GO:0007183 9.63 SMAD3 TGFB1
35 positive regulation of nitric oxide biosynthetic process GO:0045429 9.63 IL6 SMAD3 TNF
36 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.61 IL6 TNF
37 extrinsic apoptotic signaling pathway GO:0097191 9.61 SMAD3 TGFB1 TNF
38 regulation of striated muscle tissue development GO:0016202 9.58 SMAD3 TGFB1
39 regulation of binding GO:0051098 9.54 SMAD3 TGFB1
40 positive regulation of bone mineralization GO:0030501 9.54 BMP6 SMAD3 TGFB1
41 positive regulation of extracellular matrix assembly GO:1901203 9.52 SMAD3 TGFB1
42 positive regulation of mononuclear cell migration GO:0071677 9.51 TGFB1 TNF
43 negative regulation of mitotic cell cycle GO:0045930 9.43 SMAD3 TGFB1 TNF
44 wound healing GO:0042060 9.26 DCN IL6 SMAD3 TGFB1
45 evasion or tolerance of host defenses by virus GO:0019049 9.16 SMAD3 TGFB1
46 negative regulation of fat cell differentiation GO:0045599 8.92 IL6 SMAD3 TGFB1 TNF
47 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.07 BMP6 DCN IL6 SMAD3 TGFB1 TNF

Molecular functions related to Localized Scleroderma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.46 BMP6 IL6 TGFB1 TNF
2 collagen binding GO:0005518 9.43 DCN MMP13 SMAD3
3 transforming growth factor beta receptor binding GO:0005160 9.13 BMP6 SMAD3 TGFB1
4 growth factor activity GO:0008083 8.92 BMP6 CTGF IL6 TGFB1

Sources for Localized Scleroderma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....